Phenylketonuria Treatment Segmentation
The market is segmented on the basis of drug type into Palynziq, Kuvan, SYNB1618 and others. Among these segments, the Kuvan drug segment is estimated to capture the largest market share in the year 2021. Kuvan drug contains the oral pharmaceutical formulation BH4, which is known to stimulate the activity of phenylalanine hydroxylase enzyme to metabolize phenylalanine into tyrosine.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Type |
|
|
By Route of Administration |
|
|
By End Users |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of phenylketonuria treatment is evaluated at USD 843.44 million.
Phenylketonuria Treatment Market size was valued at USD 794.16 million in 2024 and is set to exceed USD 1.98 billion by 2037, expanding at over 7.3% CAGR during the forecast period i.e., between 2025-2037.
North America industry is likely to hold largest revenue share by 2037, attributed to rising research and development activities for novel drugs, coupled with favourable government regulations for the treatment of phenylketonuria.
The major players in the market are Ultragenyx Pharmaceutical, PTC Therapeutics, BioMarin, Homology Medicines, Inc., SOM BIOTECH, Nestle Health Science, American Gene Technologies Inc., Rubius Therapeutics, Inc., Synlogic, and others.
